Is Elon's Empire Crumbling?
Jeff Brown - the legend who called Tesla and Nvidia early - says Elon is about to launch a $25T AI revolution. This isn't another chatbot. It's real-world AI that could 14X the impact of ChatGPT. But after July 23rd, it may be too late.
How to manage ADHD at work and turn it into a strength
NEW YORK (AP) — Jeremy Didier had taken her son to a psychologist for a when she spotted an article about women with the condition. As she read it in the waiting room, she thought to herself: They're describing me.
Lawmakers Investigate Whether Pfizer Delayed COVID-19 Vaccine Results For Political Reasons
House Judiciary subpoenas ex-Pfizer exec Philip Dormitzer amid claims the COVID-19 vaccine announcement was delayed to avoid influencing the 2020 election.
FDA Submission Expected This Summer - Invest Before It Happens - Ad
This company is making heart disease easier to detect with AI. Their tech has officially been designated a "Breakthrough" by the FDA. You now have an opportunity to get in at a potential inflection point.
Medicaid, food aid recipients worry about safety net cuts in bill sent to Trump
JEFFERSON CITY, Mo. (AP) — Supporters of the that Congress has sent to President Donald Trump say the changes to Medicaid, food aid and other programs will encourage personal responsibility and halt those scamming the system.
AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment
AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ivonescimab.
Do These 4 Things to Your Bank Account Now ... - Ad
A sweeping U.S. policy could soon let the government track-or even freeze-your bank account. But there are 4 simple steps you can take right now to protect your savings before it's potentially too late.
Trump administration sues California over egg prices and blames animal welfare laws
The Trump administration is suing the state of California to block animal welfare laws that it says unconstitutionally helped send egg prices soaring. But a group that spearheaded the requirements pushed back, blaming bird flu for the hit to consumers' pocketbooks.
Chemical maker DuPont agrees to $27M settlement in polluted water lawsuit in upstate New York
HOOSICK FALLS, N.Y. (AP) — Chemical maker DuPont has agreed to a $27 million settlement to resolve a nearly decade-long lawsuit over the contamination of an upstate New York village's water supply.
Stunning Trump Policy Unlocks Upfront Cash Payouts - Ad
The U.S. has collected $15B from Trump's tariffs - and now, thanks to Title 15, you could claim your own $100-$1,000 instant upfront cash payouts. No stocks needed. Use your phone and this income technique to collect upfront payouts now.
UN says if US funding for HIV programs is not replaced, millions more will die by 2029
LONDON (AP) — Years of programs has reduced the number of people killed by the disease to the lowest levels seen in more than three decades, and provided for some of the world’s most vulnerable.
Rhythm Pharma's Oral Drug For Rare Obesity Shows Promise
Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 with regulators.
Back This Medical AI Tech - Ad
You don't often find healthcare tech company valued at $4M. HeartSciences is an exception. With $75M invested, including R&D, clinical trials, and product development, their patented AI software is approaching FDA submission, a potential major inflection point.
ProKidney Stock Shoots Up Over 8% After Hours After Staggering 515% Rally On Wednesday
ProKidney (NASDAQ: PROK) experienced a surge of 515% during Tuesday's trading session and gained additional 8.58% after-hours to $4.05 on positive Phase 2 trial results, with trading volume seeing a jump to 39.8 million shares from an average of 1.12 million.
Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?
ZyVersa gains FDA approval for emergency use of VAR 200 in a rare kidney disease case; stock jumps on high trading volume and regulatory momentum.
Tariff-Driven Cash Payouts, Right Off Your Smart Phone? - Ad
The U.S. Treasury has raked in $15B from Trump's tariffs - and now, thanks to Title 15, you could pocket $100-$1,000 upfront payouts yourself. No stocks needed. Just use your phone and my #1 income strategy to start collecting now.
Novartis Gets Swiss Approval For First Malaria Drug For Babies
Novartis' Coartem Baby wins Swiss approval as the first malaria drug for newborns under 5 kg, offering safer dosing and easier administration.
UnitedHealth, Centene Hit Hard By Guidance Shock, Trump's Medicaid Push
UnitedHealth, Centene, and Elevance suffered steep market cap losses amid earnings guidance withdrawals and potential Medicaid changes tied to new legislation.
Is Elon's Empire Crumbling? - Ad
Jeff Brown - the legend who called Tesla and Nvidia early - says Elon is about to launch a $25T AI revolution. This isn't another chatbot. It's real-world AI that could 14X the impact of ChatGPT. But after July 23rd, it may be too late.
Obesity drug prices are dropping, but getting a steady supply remains a challenge
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.
Rural hospitals brace for financial hits or even closure under Republicans' $1 trillion Medicaid cut
OMAHA, Neb. (AP) — Tyler Sherman, a nurse at a rural Nebraska hospital, is used to the area's aging farmers delaying care until they end up in his emergency room.
A 64% Dividend From Gold? - Ad
Gold is soaring. But here's what no one's talking about: a way to earn a 64% dividend-paid in real cash every 30 days. No trading. No risky mining stocks. Just one simple move in your brokerage account... and you could start collecting monthly income almost instantly.
Avadel Shareholder Seeks Board Shakeup, Citing Millions Lost On Lumryz
ASL demands Avadel replace its board over failures in marketing Lumryz and urging a review of strategic options
FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls
FDA raised safety concerns for Vyvgart Hytrulo in CIDP, while Argenx moves ARGX-119 into late-stage trials for rare neuromuscular disease.
What's inside Elon's building in Memphis will shock you - Ad
Inside Elon Musk's Memphis site lies a supercomputer built to power the world's first superhuman AI. It could make Elon a trillionaire - and new millionaires, too. With just $500, you could get in before the July 1st funding window closes.
Bill Gates Warns Of 'Perilous' Times After Trump Administration Pulls Funding From Gavi, A Group That Has Paid For Over A Billion Children's Vaccinations: 'All The Progress We've Made Is At Risk'
Bill Gates has expressed concern that cuts to funding for Gavi by the Trump administration could undo decades of progress.
Business News Digest
AP Business Digest
The Tesla Shock Nobody Sees Coming - Ad
While headlines scream "Tesla is doomed"...Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.
Pfizer Seeks Label Expansion For Hemophilia Drug After Promising Data
Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and showing good tolerability.
Viatris Eye Drops Data Shows Promise For Blurred Near Vision
Viatris and Opus Genetics report MR-141 met efficacy and safety goals in Phase 3 VEGA-3 trial for presbyopia, with strong patient-reported benefits.
Elon's Greatest Invention... Hidden in South Memphis? - Ad
In South Memphis, I uncovered what could be Elon Musk's biggest invention yet. It's so secretive, rivals are flying drones to spy on it. If you're serious about investing in AI, now's the time to see what's really going on inside those walls.
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?
Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.
Louisiana files lawsuits alleging pharmaceutical giant CVS deceived customers in text messages
NEW ORLEANS (AP) — Louisiana filed several lawsuits accusing pharmaceutical giant CVS of abusing customer information and using its dominant market position to drive up drug costs and unfairly undermine independent pharmacies, the state’s attorney general said Tuesday.
FDA Submission Expected This Summer - Invest Before It Happens - Ad
This company is making heart disease easier to detect with AI. Their tech has officially been designated a "Breakthrough" by the FDA. You now have an opportunity to get in at a potential inflection point.
Wisconsin Supreme Court delivers win for environmentalists in fight over ‘forever chemicals’
MADISON, Wis. (AP) — The Wisconsin Supreme Court delivered a victory for environmentalists on Tuesday in the fight over “forever chemicals” known as PFAS.
FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer
FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due.
Do These 4 Things to Your Bank Account Now ... - Ad
A sweeping U.S. policy could soon let the government track-or even freeze-your bank account. But there are 4 simple steps you can take right now to protect your savings before it's potentially too late.
Texas governor vetoes bill that would ban all THC products
AUSTIN, Texas (AP) — Texas Gov. Greg Abbott vetoed a bill Sunday to , allowing the flush with THC-infused vapes, gummies and other products to continue to be sold across the state.
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering
FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.